2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy.
We treated 26 patients with hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine, including nine with abdominal lymphadenopathy and of whom two had HCL-variant; 18 were previously treated. The overall response in 23 evaluable HCL patients was 100% with 87% complete remission (CR). The CR rate was 57% in patients with abdominal lymphadenopathy. Neither of the patients with HCL-variant achieved CR. Of four patients who had become refractory to 2'-deoxycoformycin, two achieved CR and one partial remission (PR). The lower response in HCL with abdominal lymphadenopathy supports the view that this represents a more resistant form of the disease.
Mercieca
J
J
Academic Department of Haematology and Cytogenetics, The Royal Marsden Hospital, London, UK.
Matutes
E
E
Emmett
E
E
Coles
H
H
Catovsky
D
D
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017338:Cladribine / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000150:complications / Q000188:drug therapy*; D008206:Lymphatic Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D017338:Cladribine